Michael Moore, chairman, Oxford BioTherapeutics
pharmafile | January 11, 2010 | Appointment | Research and Development | Oxford Biotherapeutics, Piramed, appointment, research and development
Oxford BioTherapeutics (OBT) has appointed Dr Michael Moore non-executive chairman.
He joins the company following five years spent at UK biotech Piramed, where he was chief executive until its 2008 acquisition by Roche.
Prior to that he was chief scientific officer and research director at Xenova and has previously held senior academic positions at the Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK and the Brunel Institute of Cancer Genetics and Pharmacogenomics, where he is still professor associate.
Dr Moore commented: “I am delighted to join Oxford BioTherapeutics at this exciting time in the company’s development. I have been highly impressed by OBT’s scientific and commercial approach and am very pleased to join the other distinguished members of the OBT Board and management, as we work together to set the strategic framework for the company’s continued growth and success.”
OBT recently recruited a number of other senior industry leaders in the biologics field, including new chief operating officer Jim Cornett and chief scientific officer Mike Gresser.
Related Content
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
Lonza CEO to step down in 2020
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …